Therefore, SFX-01 not only limits myeloid cell proliferation by inducing STAT1 phosphorylation but also limits mutant Shp-2-driven JMML patient-derived HSC proliferation, highlighting the therapeutic potential of SFX-01. This evidence concerns the gene STAT1 and juvenile myelomonocytic leukemia.